Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Archives of Medical Science : AMS
|
August 7, 2014
Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
Anastazia Kei, Moses Elisaf
Expert Opinion on Drug Safety
|
May 9, 2012
Nicotinic acid: clinical considerations
Anastazia Kei, Moses S Elisaf
World Journal of Diabetes
|
January 1, 2014
Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia
Anastazia Kei, Evangelos Liberopoulos, Moses Elisaf
Therapeutic Advances in Chronic Disease
|
September 4, 2015
Statin use in prediabetic patients: rationale and results to date
Anastazia Kei, Evangelos C Rizos, Moses Elisaf
Archives of Toxicology
|
May 12, 2016
The current role of thiazolidinediones in diabetes management
Christos V Rizos, Anastazia Kei, Moses S Elisaf
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
April 21, 2012
Autoimmune manifestations in patients with visceral leishmaniasis
Evangelos Liberopoulos, Anastazia Kei, Fotini Apostolou, et al.
Annals of Gastroenterology
|
April 10, 2014
Electrolyte and acid-base disorders in inflammatory bowel disease
Fotis Barkas, Evangelos Liberopoulos, Anastazia Kei, et al.
Current Vascular Pharmacology
|
February 15, 2011
What restricts the clinical use of nicotinic acid?
Anastazia Kei, Evangelos N Liberopoulos, Moses S Elisaf
Diseases (Basel, Switzerland)
|
September 30, 2017
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf
Hospital Practice (1995)
|
June 1, 2018
Diagnostic lipid changes in patients with visceral leishmaniasis
Vasilis Tsimihodimos, Anastazia Kei, Fotini Apostolou, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Archives of Medical Science : AMS
|
August 7, 2014
Nicotinic acid/laropiprant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia
Anastazia Kei, Moses Elisaf
Expert Opinion on Drug Safety
|
May 9, 2012
Nicotinic acid: clinical considerations
Anastazia Kei, Moses S Elisaf
World Journal of Diabetes
|
January 1, 2014
Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia
Anastazia Kei, Evangelos Liberopoulos, Moses Elisaf
Therapeutic Advances in Chronic Disease
|
September 4, 2015
Statin use in prediabetic patients: rationale and results to date
Anastazia Kei, Evangelos C Rizos, Moses Elisaf
Archives of Toxicology
|
May 12, 2016
The current role of thiazolidinediones in diabetes management
Christos V Rizos, Anastazia Kei, Moses S Elisaf
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
|
April 21, 2012
Autoimmune manifestations in patients with visceral leishmaniasis
Evangelos Liberopoulos, Anastazia Kei, Fotini Apostolou, et al.
Annals of Gastroenterology
|
April 10, 2014
Electrolyte and acid-base disorders in inflammatory bowel disease
Fotis Barkas, Evangelos Liberopoulos, Anastazia Kei, et al.
Current Vascular Pharmacology
|
February 15, 2011
What restricts the clinical use of nicotinic acid?
Anastazia Kei, Evangelos N Liberopoulos, Moses S Elisaf
Diseases (Basel, Switzerland)
|
September 30, 2017
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Theodosios D Filippatos, Anastazia Kei, Moses S Elisaf
Hospital Practice (1995)
|
June 1, 2018
Diagnostic lipid changes in patients with visceral leishmaniasis
Vasilis Tsimihodimos, Anastazia Kei, Fotini Apostolou, et al.
Page
of 3